Thelansis

Adenoid Cystic Carcinoma (ACC) Market Outlook Thelansis’s “Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adenoid Cystic Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact o...

  Adenoid Cystic Carcinoma (ACC) Market Outlook Thelansis’s “Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adenoid Cystic Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the ma...

Adenoid Cystic Carcinoma (ACC) Market Outlook Thelansis’s “Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adenoid Cystic Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Adenoid Cystic Carcinoma (ACC) Overview Adenoid cystic carcinoma (ACC) is a rare tumor that originates within secretory glands and accounts for a substantial portion of minor salivary, parotid, and submandibular gland malignancies. ACC can occur in other parts of the body, including the breast, skin, cervix in females, the prostate gland in males, and other areas. ACC tumors have a distinct histological pattern th...

  Adenoid cystic carcinoma (ACC) is a rare tumor that originates within secretory glands and accounts for a substantial portion of minor salivary, parotid, and submandibular gland malignancies. ACC can occur in other parts of the body, including the breast, skin, cervix in females, the prostate gland in males, and other areas. ACC tumors have a distinct histological pattern that consists of abnormal "nests" or cords of specific cells (epithelial cells) that surround and infiltrate ducts or glandular structures within the affected organ. Typically, these structures are filled with a mucous-like material or have abnormal fibrous membranes. Such characteristics are visible during a microscopic examination of tumor cells in a biopsy sample. The most common course of treatment for ACC is surgical excision, which is typically followed by external radiation of the surgical bed and the draining of the named nerves in the head and neck. ACC incidence ranges from 0.5 to 0.72 c...

Indication name: Adenoid cystic carcinoma (ACC) Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma, a type of cancer that begins in glandular tissues. It most commonly arises in the major and minor salivary glands of the head and neck. It can also occur in the breast, uterus, or other locations in the body. Etiology- The exact cause of adenoid cystic carcinoma is unknown.  New studies spaculate that a protein produced by the fusion of two transcription factor genes, MYB-NFIB, plays a role in the development of ACC tumors. This fusion protein is found in up to 90-95 % of ACC tumors. Mutations in the NOTCH1 gene are also associated with ACC, particularly in patients with recurrent or metastatic disease. Patients with NOTCH1 gene mutations have a worse prognosis. Epidemiology- Every year, about 1,200 individuals are diagnosed with ACC in the United States. 58% of ACC patients exhibit tumors in the oral cavity, salivary glands, and pharynx, 17% in the respirator...